{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:45:57Z","timestamp":1760784357732,"version":"3.40.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejmech.2017.09.075","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T11:00:34Z","timestamp":1507719634000},"page":"188-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design"],"prefix":"10.1016","volume":"141","author":[{"given":"Chiara","family":"Zagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venerando","family":"Pistar\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana A.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogerio M.","family":"Castilho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Chiacchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5039-2151","authenticated-orcid":false,"given":"Antonio","family":"Rescifina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.09.075_bib1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/sj.embor.embor941","article-title":"Regulating histone acetyltransferases and deacetylases","volume":"4","author":"Legube","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2017.09.075_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2017.09.075_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2017.09.075_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2017.09.075_bib5","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/MCB.21.8.2726-2735.2001","article-title":"Histone acetylation at promoters is differentially affected by specific activators and repressors","volume":"21","author":"Deckert","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejmech.2017.09.075_bib6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.09.075_bib7","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.09.075_bib8","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2017.09.075_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14728222.9.4.809","article-title":"Histone deacetylase inhibitors: insights into mechanisms of lethality","volume":"9","author":"Rosato","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2017.09.075_bib10","doi-asserted-by":"crossref","first-page":"e58672","DOI":"10.1371\/journal.pone.0058672","article-title":"Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer","volume":"8","author":"Giudice","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2017.09.075_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2017.09.075_bib12","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1021\/jm800251w","article-title":"Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor","volume":"51","author":"Zhou","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.09.075_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.09.075_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2017.09.075_bib15","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.09.075_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.fob.2013.12.003","article-title":"NF\u03baB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC)","volume":"4","author":"Almeida","year":"2014","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2017.09.075_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4252\/wjsc.v6.i5.511","article-title":"Histone modifications: targeting head and neck cancer stem cells","volume":"6","author":"Le","year":"2014","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.ejmech.2017.09.075_bib18","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.09.075_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2017.09.075_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/humu.10257","article-title":"PTEN: one gene, many syndromes","volume":"22","author":"Eng","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2017.09.075_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1248\/bpb.30.1624","article-title":"PTEN: its deregulation and tumorigenesis","volume":"30","author":"Maehama","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2017.09.075_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcb.20179","article-title":"Regulation of histone deacetylase activities","volume":"93","author":"Sengupta","year":"2004","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.ejmech.2017.09.075_bib23","first-page":"345","article-title":"QSAR modeling of sulfonamide inhibitors of histone deacetylase","volume":"5","author":"Jaiswal","year":"2006","journal-title":"Internet Electron. J. Mol. Des."},{"key":"10.1016\/j.ejmech.2017.09.075_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2017.09.075_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbrc.2011.01.109","article-title":"Integrin alpha beta 1, alpha(v)beta, alpha(6)beta effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance","volume":"406","author":"Sansing","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2017.09.075_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2174\/157018011794839475","article-title":"Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines","volume":"8","author":"Patel","year":"2011","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2017.09.075_bib27","first-page":"103","article-title":"Cisplatin-based chemotherapy options for recurrent and\/or metastatic squamous cell cancer of the head and neck","volume":"5","author":"Pendleton","year":"2013","journal-title":"Clin. Med. Insights Ther."},{"key":"10.1016\/j.ejmech.2017.09.075_bib28","first-page":"51","article-title":"The prognostic function of biomarkers in head and neck squamous cell carcinomas HNSCC","volume":"1","author":"Li","year":"2011","journal-title":"Cancer Biol."},{"key":"10.1016\/j.ejmech.2017.09.075_bib29","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2017.09.075_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2017.09.075_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11864-011-0176-y","article-title":"Current treatment options for metastatic head and neck cancer","volume":"13","author":"Price","year":"2012","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ejmech.2017.09.075_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1107\/S0907444911054515","article-title":"PDB_REDO: constructive validation, more than just looking for errors","volume":"68","author":"Joosten","year":"2012","journal-title":"Acta Crystallogr. D."},{"key":"10.1016\/j.ejmech.2017.09.075_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jcc.21600","article-title":"Gabedit-a graphical user interface for computational chemistry softwares","volume":"32","author":"Allouche","year":"2011","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2017.09.075_bib34","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00894-007-0233-4","article-title":"Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements","volume":"13","author":"Stewart","year":"2007","journal-title":"J.\u00a0Mol. Mod."},{"key":"10.1016\/j.ejmech.2017.09.075_bib35","series-title":"Stewart Computational Chemistry","article-title":"MOPAC2016","author":"Stewart","year":"2016"},{"key":"10.1016\/j.ejmech.2017.09.075_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:JCAM.0000035186.90683.f2","article-title":"VEGA - an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming","volume":"18","author":"Pedretti","year":"2004","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.09.075_bib37","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2017.09.075_bib38","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/ci500209e","article-title":"AutoDock4(Zn): an improved AutoDock force field for small-molecule docking to zinc metalloproteins","volume":"54","author":"Santos-Martins","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2017.09.075_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1087057104265386","article-title":"Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines","volume":"9","author":"Mueller","year":"2004","journal-title":"J.\u00a0Biomol. Screen."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417307900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417307900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T01:36:14Z","timestamp":1530236174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417307900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":39,"alternative-id":["S0223523417307900"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.09.075","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.09.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}